NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Completed
Hanmi Pharmaceutical Company Limited
Phase 2
The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the
efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a 2nd line
monotherapy agent in lung adenocarcinoma patients with acquired resistance to prior EGFR
tyrosine kinase inhibitors (TKIs).
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Completed
National OncoVenture
Phase 2
The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the
efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a 2nd line
monotherapy agent in lung adenocarcinoma patients with acquired resistance to prior EGFR
tyrosine kinase inhibitors (TKIs).
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Completed
National OncoVenture
Phase 1/Phase 2
[Phase I] The main objective of this study is to evaluate the safety, tolerability and
determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab
[Phase II] The main objective of this study is to evaluate anticancer activity through
determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab in patients with HER-2 positive advanced gastric cancer
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Completed
Hanmi Pharmaceutical Company Limited
Phase 1/Phase 2
[Phase I] The main objective of this study is to evaluate the safety, tolerability and
determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab
[Phase II] The main objective of this study is to evaluate anticancer activity through
determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and
Trastuzumab in patients with HER-2 positive advanced gastric cancer
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
